Recent Updates
Recently added Catalysts
SPTX Positive Sentiment

SPT-300, an Oral Prodrug of Allopregnanolone, Potently Reduces Salivary Cortisol Response to the Trier Social Stress Test in a Randomized, Placebo-Controlled Phase 2a Study in Healthy Participants

Thursday, December 19, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the results of a Phase 2a study on SPT-300, an oral prodrug of allopregnanolone. The study demonstrated that SPT-300 significantly reduces salivary cortisol levels in response to the Trier Social Stress Test among healthy participants. This suggests its potential use in managing stress-related disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • SPT-300 effectively reduces salivary cortisol response.
  • The study was randomized and placebo-controlled.
  • Results indicate potential for managing stress-related conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)

Full Press Release Details

Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - December 19, 2024
SPT-300, an Oral Prodrug of Allopregnanolone, Potently Reduces Salivary Cortisol Response to the Trier Social Stress Test in a Randomized, Placebo-Controlled Phase 2a Study in Healthy Participants

Frequently Asked Questions

What is SPT-300?

SPT-300 is an oral prodrug of allopregnanolone aimed at reducing stress responses.

What were the results of the Phase 2a study?

The study found that SPT-300 significantly reduced salivary cortisol in participants.

What is the Trier Social Stress Test?

It is a standardized test used to assess stress responses in individuals.

Who participated in the study?

The study involved healthy participants in a randomized, placebo-controlled design.

ShareAdd on Google
Tags: SPTX Viatris Investor Conferences Healthcare SPT-300 cortisol stress test allopregnanolone
Last updated: Dec 19, 2024

Biotech snapshot

Cash runway
$273M liquidity · $22M/mo burn
~12 mo
Low dilution risk
Lead asset
SPT-300Phase 2
Major Depressive Disorder (MDD) →